Loading...
Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis.
In a double-blind double-placebo crossover study naproxen (500-750 mg daily) was found to be equivalent to phenylbutazone (400-600 mg daily) in the control of disease activity in 20 patients suffering from ankylosing spondylitis during a two times 5-week trial period. No serious side effects were ob...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
1978
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1000198/ https://ncbi.nlm.nih.gov/pubmed/343727 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|